Stock Comparison

JNJ vs TARA

Johnson & Johnson vs Protara Therapeutics Inc

The Verdict

TARA takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

TARA

Protara Therapeutics Inc

4.5

out of 10

Proceed with Caution

Head-to-Head

$557.1B

Market Cap

$277M

26.5

P/E Ratio

-3.6

21.8%

Profit Margin

N/A

26.3%

Return on Equity

-38.7%

0.6

Debt-to-Equity

N/A

Conservative

Overall Risk

Aggressive

1.0

DVR Score

4.5

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

TARA4.5/10

Protara Therapeutics (TARA) continues to represent a high-risk, high-reward investment opportunity, largely tied to the binary outcome of TARA-002. While the recent FDA Orphan Drug Designation for TARA-002 in specific lymphatic malformations reinforces its potential for market leadership and addresses a significant unmet medical need, recent financial updates temper enthusiasm. Q1 2026 saw a widen...

Full TARA Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.